ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,614.56
-2.70%
Dow Jones
41,911.71
-2.08%
US Dollar vs MXN
20.35254
-0.01%
Brent Oil
69.04
0.00%
Bitcoin
80,244.01
2.26%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) Noticias

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:AMEX:CANF
FechaHoraFuenteTítuloSímboloCompañía
03/03/202505:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
03/03/202505:00GlobeNewswire Inc.Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological BenefitsAMEX:CANFCan Fite BioPharma Ltd
18/02/202506:00GlobeNewswire Inc.Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's NamodenosonAMEX:CANFCan Fite BioPharma Ltd
14/02/202516:33Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:CANFCan Fite BioPharma Ltd
10/02/202506:10GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25AMEX:CANFCan Fite BioPharma Ltd
05/02/202506:00GlobeNewswire Inc.Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025AMEX:CANFCan Fite BioPharma Ltd
27/01/202506:00GlobeNewswire Inc.US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity DrugAMEX:CANFCan Fite BioPharma Ltd
30/12/202406:00GlobeNewswire Inc.Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug NamodenosonAMEX:CANFCan Fite BioPharma Ltd
04/12/202406:00GlobeNewswire Inc.8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson DrugAMEX:CANFCan Fite BioPharma Ltd
14/11/202415:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:CANFCan Fite BioPharma Ltd
11/11/202406:00GlobeNewswire Inc.Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialAMEX:CANFCan Fite BioPharma Ltd
04/11/202406:08GlobeNewswire Inc.Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaAMEX:CANFCan Fite BioPharma Ltd
18/10/202408:06GlobeNewswire Inc.Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonAMEX:CANFCan Fite BioPharma Ltd
09/10/202406:00GlobeNewswire Inc.FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
07/10/202406:00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29AMEX:CANFCan Fite BioPharma Ltd
24/09/202406:00GlobeNewswire Inc.Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary OsteoarthritisAMEX:CANFCan Fite BioPharma Ltd
16/09/202406:00GlobeNewswire Inc.Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthAMEX:CANFCan Fite BioPharma Ltd
08/09/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
06/09/202415:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CANFCan Fite BioPharma Ltd
30/08/202415:18Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
30/08/202415:16Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CANFCan Fite BioPharma Ltd
30/08/202415:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CANFCan Fite BioPharma Ltd
29/08/202407:15GlobeNewswire Inc.Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAMEX:CANFCan Fite BioPharma Ltd
08/08/202418:01GlobeNewswire Inc.Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsAMEX:CANFCan Fite BioPharma Ltd
29/07/202406:00GlobeNewswire Inc.Can-Fite Provides Namodenoson Patent UpdateAMEX:CANFCan Fite BioPharma Ltd
17/07/202406:00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8AMEX:CANFCan Fite BioPharma Ltd
11/07/202406:00GlobeNewswire Inc.Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
01/07/202406:00GlobeNewswire Inc.Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with NamodenosonAMEX:CANFCan Fite BioPharma Ltd
28/06/202406:00Business WirePositive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner VetbiolixAMEX:CANFCan Fite BioPharma Ltd
24/06/202406:00Business WireCan-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the LiverAMEX:CANFCan Fite BioPharma Ltd
 Showing the most relevant articles for your search:AMEX:CANF

Su Consulta Reciente

BIT
UC4SRT
Unicredit Bank
BIT
UC526U
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios